Nrf2 is a transcription factor critical for protecting the brain against oxidative stress and is decreased in Alzheimer's disease (AD) patients, making it a potential therapeutic target. The Curran lab previously identified a novel regulator, WDR23. Now, in a new study by Liu et al., they demonstrate that knocking out WDR23 in the 3xTg-AD mouse improves spatial working memory, interestingly, while increasing a measure of AD-like pathology. Their work brings up several interesting new questions and adds to a growing body of literature that highlights how the relationship between cognition and amyloid pathology is not as clearcut as once thought.
TalalayPDinkova-KostovaATHoltzclawWD. Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis. Adv Enzyme Regul2003; 43: 121–134.
2.
MotohashiHYamamotoM. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med2004; 10: 549–557.
3.
AhmedSMULuoLNamaniA, et al.Nrf2 signaling pathway: pivotal roles in inflammation. Biochim Biophys Acta Mol Basis Dis2017; 1863: 585–597.
4.
LuchkovaAMataACadenasS. Nrf2 as a regulator of energy metabolism and mitochondrial function. FEBS Lett2024; 598: 2092–2105.
5.
RummelNGButterfieldDA. Altered metabolism in Alzheimer disease brain: role of oxidative stress. Antioxid Redox Signal2022; 36: 1289–1305.
6.
TwarowskiBHerbetM. Inflammatory processes in Alzheimer’s disease-pathomechanism, diagnosis and treatment: a review. Int J Mol Sci2023; 24: 6518.
7.
Silva-PalaciosAOstolga-ChavarríaMZazuetaC, et al.Nrf2: molecular and epigenetic regulation during aging. Ageing Res Rev2018; 47: 31–40.
8.
CuadradoAKüglerSLastres-BeckerI. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. Redox Biol2018; 14: 522–534.
9.
CuiYMaSZhangC, et al.Pharmacological activation of the Nrf2 pathway by 3H-1, 2-dithiole-3-thione is neuroprotective in a mouse model of Alzheimer disease. Behav Brain Res2018; 336: 219–226.
10.
KobayashiAKangM-IOkawaH, et al.Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol2004; 24: 7130–7139.
11.
ItohKChibaTTakahashiS, et al.An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun1997; 236: 313–322.
LiuJDuangjanCPhanNM, et al.Loss of WDR23 slows the rate of age-related cognitive decline with elevated amyloid burden. J Alzheimers Dis2025; 106: 218–229.
14.
SmithMAHiraiKHsiaoK, et al.Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem1998; 70: 2212–2215.
15.
LeeHCasadesusGZhuX, et al.Perspectives on the amyloid-beta cascade hypothesis. J Alzheimers Dis2004; 6: 137–145.
16.
BehlC. In 2024, the amyloid-cascade-hypothesis still remains a working hypothesis, no less but certainly no more. Front Aging Neurosci2024; 16: 1459224.
17.
LuWShueFKurtiA, et al.Amyloid pathology and cognitive impairment in hAβ-KI and APPSAA-KI mouse models of Alzheimer’s disease. Neurobiol Aging2025; 145: 13–23.
18.
DodartJ-CBalesKRGannonKS, et al.Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nat Neurosci2002; 5: 452–457.
19.
KotilinekLABacskaiBWestermanM, et al.Reversible memory loss in a mouse transgenic model of Alzheimer’s disease. J Neurosci2002; 22: 6331–6335.
20.
van DyckCHSwansonCJAisenP, et al.Lecanemab in early Alzheimer’s disease. N Engl J Med2023; 388: 9–21.
21.
RodrigueKMKennedyKMDevousMD, et al.β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology2012; 78: 387–395.
22.
FarrellMEKennedyKMRodrigueKM, et al.Association of longitudinal cognitive decline with amyloid burden in middle-aged and older adults: evidence for a dose-response relationship. JAMA Neurol2017; 74: 830–838.
23.
AizensteinHJNebesRDSaxtonJA, et al.Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol2008; 65: 1509–1517.
24.
JungYWhitwellJLDuffyJR, et al.Regional β-amyloid burden does not correlate with cognitive or language deficits in Alzheimer’s disease presenting as aphasia. Eur J Neurol2016; 23: 313–319.
25.
FrisoniGBAltomareDThalDR, et al.The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci2022; 23: 53–66.
26.
GranzottoAVisselBSensiSL. Lost in translation: inconvenient truths on the utility of mouse models in Alzheimer’s disease research. eLife2024; 13: e90633.
27.
SharmaASancesSWorkmanMJ, et al.Multi-lineage human iPSC-derived platforms for disease modeling and drug discovery. Cell Stem Cell2020; 26: 309–329.
28.
CerneckisJBuGShiY. Pushing the boundaries of brain organoids to study Alzheimer’s disease. Trends Mol Med2023; 29: 659–672.
29.
XiaBWeiJMaX, et al.Conditional knockout of MET receptor tyrosine kinase in cortical excitatory neurons leads to enhanced learning and memory in young adult mice but early cognitive decline in older adult mice. Neurobiol Learn Mem2021; 179: 107397.
30.
HongSBeja-GlasserVFNfonoyimBM, et al.Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science2016; 352: 712–716.
